JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling

Overactive Janus kinases (JAKs) are known to drive leukemia, making them well-suited targets for treatment. We sought to identify new JAK-activating mutations and instead found a JAK1-inactivating pseudokinase mutation, V666G. In contrast to other pseudokinase mutations that canonically lead to an a...

Descripción completa

Detalles Bibliográficos
Autores principales: Grant, Alice H., Rodriguez, Alejandro C., Rodriguez Moncivais, Omar J., Sun, Shengjie, Li, Lin, Mohl, Jonathon E., Leung, Ming-Ying, Kirken, Robert A., Rodriguez, Georgialina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095075/
https://www.ncbi.nlm.nih.gov/pubmed/37047778
http://dx.doi.org/10.3390/ijms24076805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095075/
https://www.ncbi.nlm.nih.gov/pubmed/37047778
http://dx.doi.org/10.3390/ijms24076805

Ejemplares similares